Corcept Therapeutics Incorporated

NasdaqCM:CORT Stock Report

Market Cap: US$2.6b

Corcept Therapeutics Management

Management criteria checks 4/4

Corcept Therapeutics' CEO is Joseph Belanoff, appointed in Jan 1999, has a tenure of 25.17 years. total yearly compensation is $7.35M, comprised of 12.2% salary and 87.8% bonuses, including company stock and options. directly owns 2.74% of the company’s shares, worth $71.70M. The average tenure of the management team and the board of directors is 3.3 years and 22.4 years respectively.

Key information

Joseph Belanoff

Chief executive officer

US$7.4m

Total compensation

CEO salary percentage12.2%
CEO tenure25.2yrs
CEO ownership2.7%
Management average tenure3.3yrs
Board average tenure22.4yrs

Recent management updates

Recent updates

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Dec 23
After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Nov 07
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Jun 23
Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Feb 16
Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Jan 11
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Corcept Therapeutics starts phase 2 trial of its ALS treatment

Oct 11

Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Sep 27
Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Corcept extends distribution agreement for Cushing’s syndrome drug

Sep 23

Corcept Therapeutics: A Status Check

Sep 06

Corcept cut to Hold at Truist on balanced risk-reward setup

Aug 01

Corcept Therapeutics begins phase 3 trial of relacorilant for ovarian cancer

Jun 29

I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease

Jun 09
I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease

Is Now The Time To Put Corcept Therapeutics (NASDAQ:CORT) On Your Watchlist?

Feb 23
Is Now The Time To Put Corcept Therapeutics (NASDAQ:CORT) On Your Watchlist?

CEO Compensation Analysis

How has Joseph Belanoff's remuneration changed compared to Corcept Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

US$105m

Sep 30 2023n/an/a

US$91m

Jun 30 2023n/an/a

US$94m

Mar 31 2023n/an/a

US$94m

Dec 31 2022US$7mUS$896k

US$101m

Sep 30 2022n/an/a

US$117m

Jun 30 2022n/an/a

US$113m

Mar 31 2022n/an/a

US$112m

Dec 31 2021US$11mUS$844k

US$113m

Sep 30 2021n/an/a

US$106m

Jun 30 2021n/an/a

US$98m

Mar 31 2021n/an/a

US$99m

Dec 31 2020US$6mUS$770k

US$106m

Sep 30 2020n/an/a

US$109m

Jun 30 2020n/an/a

US$114m

Mar 31 2020n/an/a

US$106m

Dec 31 2019US$5mUS$708k

US$94m

Sep 30 2019n/an/a

US$87m

Jun 30 2019n/an/a

US$78m

Mar 31 2019n/an/a

US$76m

Dec 31 2018US$6mUS$680k

US$75m

Sep 30 2018n/an/a

US$152m

Jun 30 2018n/an/a

US$148m

Mar 31 2018n/an/a

US$142m

Dec 31 2017US$4mUS$647k

US$129m

Compensation vs Market: Joseph's total compensation ($USD7.35M) is about average for companies of similar size in the US market ($USD6.32M).

Compensation vs Earnings: Joseph's compensation has been consistent with company performance over the past year.


CEO

Joseph Belanoff (66 yo)

25.2yrs

Tenure

US$7,352,757

Compensation

Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...


Leadership Team

NamePositionTenureCompensationOwnership
Joseph Belanoff
Co-Founder25.2yrsUS$7.35m2.74%
$ 71.7m
Atabak Mokari
CFO & Treasurer3yrsUS$1.89m0.0092%
$ 241.4k
Hazel Hunt
Chief Scientific Officer3.7yrsUS$3.11m0.090%
$ 2.4m
Sean Maduck
President of Endocrinology7.9yrsUS$3.71m0.10%
$ 2.7m
Gary Robb
Chief Business Officer & Secretary10.2yrsUS$3.20m0.044%
$ 1.1m
Joseph Lyon
Chief Accounting Officer3.7yrsno data0.0071%
$ 185.3k
Amy Flood
Chief Human Resources & Communications Officer2.7yrsno datano data
William Guyer
Chief Development Officer2.6yrsno data0.0058%
$ 152.8k
Monica Tellado
President of Emerging Marketsless than a yearno datano data
Roberto Vieira
President of Oncologyless than a yearno datano data

3.3yrs

Average Tenure

52.5yo

Average Age

Experienced Management: CORT's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Joseph Belanoff
Co-Founder25.2yrsUS$7.35m2.74%
$ 71.7m
George Baker
Independent Director25.2yrsUS$311.77k5.13%
$ 134.5m
David Mahoney
Independent Director19.7yrsUS$328.27k1.17%
$ 30.8m
Charles Nemeroff
Member of Scientific Advisory Boardno datano datano data
James Wilson
Independent Chairman25.2yrsUS$678.99k2.14%
$ 56.1m
Florian Holsboer
Member of Scientific Advisory Boardno datano datano data
Bruce McEwen
Member of Scientific Advisory Boardno datano datano data
Ned Kalin
Member of Scientific Advisory Boardno datano datano data
Edo Kloet
Member of Scientific Advisory Boardno datano datano data
Gregg Alton
Independent Director4yrsUS$330.77k0%
$ 0
K. Ranga Krishnan
Member of Scientific Advisory Boardno datano datano data
Kimberly Park
Independent Director4.5yrsUS$307.77k0%
$ 0

22.4yrs

Average Tenure

67.5yo

Average Age

Experienced Board: CORT's board of directors are seasoned and experienced ( 22.4 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.